

Lionel AdÃ¡s

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6712163/publications.pdf>

Version: 2024-02-01

103
papers

5,039
citations

147801

31
h-index

102487

66
g-index

106
all docs

106
docs citations

106
times ranked

4643
citing authors

#	ARTICLE	IF	CITATIONS
1	Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients*. British Journal of Dermatology, 2022, 186, 564-574.	1.5	174
2	Clinical, pathological, and molecular features of myelodysplasia cutis. Blood, 2022, 139, 1251-1253.	1.4	15
3	The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. Cancer Journal (Sudbury, Mass), 2022, 28, 29-36.	2.0	5
4	Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study. Open Forum Infectious Diseases, 2022, 9, ofac088.	0.9	4
5	A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. British Journal of Haematology, 2022, 198, 535-544.	2.5	12
6	Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood, 2022, 140, 756-768.	1.4	48
7	Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia, 2022, 36, 1585-1595.	7.2	24
8	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplantation, 2022, 57, 1365-1372.	2.4	3
9	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Advances, 2022, 6, 5132-5145.	5.2	43
10	A multiparametric niche-like drug screening platform in acute myeloid leukemia. Blood Cancer Journal, 2022, 12, .	6.2	6
11	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
12	Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia, 2021, 35, 225-228.	7.2	9
13	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Advances, 2021, 5, 176-184.	5.2	56
14	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Haematologica, 2021, 106, 1414-1422.	3.5	17
15	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia, 2021, 35, 2720-2724.	7.2	29
16	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	1.4	36
17	Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes. Hemato, 2021, 2, 329-346.	0.6	2
18	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 2021, 138, 507-519.	1.4	40

#	ARTICLE	IF	CITATIONS
19	Eprenetapopt Plus Azacitidine in <i>TP53</i> -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myéloblastoses (GFM). <i>Journal of Clinical Oncology</i> , 2021, 39, 1575-1583.	1.6	169
20	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. <i>Leukemia</i> , 2021, 35, 3542-3550.	7.2	97
21	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. <i>Blood Cancer Journal</i> , 2021, 11, 129.	6.2	0
22	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021, 11, 3198-3213.	9.4	38
23	Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. <i>Leukemia</i> , 2021, 35, 2731-2733.	7.2	27
24	<i>UBA1</i> Variations in Neutrophilic Dermatitis Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 1349.	4.1	71
25	Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series. <i>Frontiers in Immunology</i> , 2021, 12, 715053.	4.8	6
26	Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954). <i>Blood</i> , 2021, 138, 242-242.	1.4	10
27	Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID). <i>Blood</i> , 2021, 138, 1496-1496.	1.4	1
28	How we manage adults with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2020, 189, 1016-1027.	2.5	60
29	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102446.	5.8	13
30	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	3.4	21
31	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.	5.2	49
32	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweet's Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.7	23
33	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1160-1170.	2.0	9
34	Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13.	1.4	4
35	A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	55
36	Germline DDX41 mutations define a significant entity within adult MDS/AML patients. <i>Blood</i> , 2019, 134, 1441-1444.	1.4	153

#	ARTICLE	IF	CITATIONS
37	Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made. <i>Lancet Haematology</i> , 2019, 6, e290-e291.	4.6	5
38	Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2594-2596.	1.3	7
39	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. <i>Haematologica</i> , 2019, 104, 1565-1571.	3.5	39
40	Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. <i>Blood Advances</i> , 2019, 3, 3579-3589.	5.2	7
41	Inflammatory disorders associated with trisomy 8 in myelodysplastic syndromes: French retrospective case-control study. <i>European Journal of Haematology</i> , 2019, 102, 63-69.	2.2	20
42	Gastrointestinal Behçet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1782-1788.	1.3	22
43	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	3.5	62
44	Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. <i>Annals of Hematology</i> , 2018, 97, 541-542.	1.8	0
45	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. <i>Leukemia Research</i> , 2018, 71, 67-74.	0.8	4
46	Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies. <i>British Journal of Haematology</i> , 2018, 182, 843-850.	2.5	18
47	<i>NPM1</i> mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. <i>Haematologica</i> , 2018, 103, e455-e457.	3.5	22
48	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , 2018, 31, 174-181.	6.1	72
49	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 2066-2069.	7.2	4
50	Autoimmune manifestations associated with myelodysplastic syndromes. <i>Annals of Hematology</i> , 2018, 97, 2015-2023.	1.8	63
51	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. <i>Leukemia Research</i> , 2017, 63, 72-77.	0.8	14
52	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. <i>Autoimmunity Reviews</i> , 2017, 16, 903-910.	5.8	32
53	Preclinical modeling of myelodysplastic syndromes. <i>Leukemia</i> , 2017, 31, 2702-2708.	7.2	34
54	Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. <i>Leukemia Research</i> , 2016, 47, 136-141.	0.8	49

#	ARTICLE	IF	CITATIONS
55	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. <i>Rheumatology</i> , 2016, 55, 291-300.	1.9	170
56	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. <i>Leukemia</i> , 2016, 30, 1416-1418.	7.2	16
57	Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. <i>Blood</i> , 2015, 125, 3447-3454.	1.4	104
58	Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 1214-1219.	0.8	2
59	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. <i>Leukemia Research</i> , 2015, 39, 501-504.	0.8	46
60	Evolving characteristics and outcome of secondary acute promyelocytic leukemia (<scp>APL</scp>): A prospective analysis by the <scp>F</scp>renchâ€<scp>B</scp>elgianâ€<scp>S</scp>wiss <scp>APL</scp> group. <i>Cancer</i> , 2015, 121, 2393-2399.	4.1	15
61	Azacitidine for the treatment of relapsed and refractory AML in older patients. <i>Leukemia Research</i> , 2015, 39, 124-130.	0.8	63
62	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 29-33.	0.8	16
63	Myelodysplastic syndromes. <i>Lancet, The</i> , 2014, 383, 2239-2252.	13.7	352
64	Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. <i>Leukemia Research</i> , 2014, 38, 751-755.	0.8	141
65	Prognostic Factors of Infections and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA): A Prospective Study. <i>Blood</i> , 2014, 124, 1917-1917.	1.4	0
66	BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3261-3261.	1.4	0
67	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013, 122, 2943-2964.	1.4	567
68	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	1.6	265
69	Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE). <i>Blood</i> , 2013, 122, 1406-1406.	1.4	2
70	A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients. <i>Blood</i> , 2013, 122, 1513-1513.	1.4	2
71	Outcome Of Patients With IPSS Intermediate (int) Or High Risk Myelodysplastic Syndrome (MDS) According To Donor Availability: A Multicenter Prospective Non Interventional Study For The SFCM-TC and GFM. <i>Blood</i> , 2013, 122, 301-301.	1.4	7
72	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. <i>Blood</i> , 2013, 122, 389-389.	1.4	6

#	ARTICLE	IF	CITATIONS
73	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). Blood, 2013, 122, 620-620.	1.4	2
74	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL – Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. Blood, 2013, 122, 495-495.	1.4	0
75	Impact Of Myelofibrosis (MF) In MDS Treated With Azacitidine (AZA). A Single Center Study. Blood, 2013, 122, 1539-1539.	1.4	1
76	A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM). Blood, 2013, 122, 2750-2750.	1.4	2
77	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism. Blood, 2013, 122, 2761-2761.	1.4	1
78	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood, 2012, 120, 5084-5085.	1.4	50
79	Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine. Blood, 2012, 120, 1706-1706.	1.4	3
80	Impact of Cytogenetics and Cytogenetic Response On Outcome in MDS Treated with Azacitidine (AZA).. Blood, 2012, 120, 2807-2807.	1.4	13
81	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf) Tj ETQq1 1 0.784314 rgBT /Ove		
82	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). Blood, 2012, 120, 3811-3811.	1.4	1
83	Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q. Blood, 2012, 120, 3833-3833.	1.4	7
84	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood, 2012, 120, 422-422.	1.4	3
85	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). Blood, 2012, 120, 890-890.	1.4	1
86	Equivalent Outcome Between Reduced Intensity Versus Conventional Myeloablative Conditioning Hematopoietic Stem Cell Transplantation for Patients Older Than 35 Years with Acute Myeloid Leukemia.. Blood, 2012, 120, 3103-3103.	1.4	0
87	Prognostic Factors of Severe Infections, and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA). A Single Center Study On 144 Patients. Blood, 2012, 120, 3812-3812.	1.4	7
88	Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.. Blood, 2012, 120, 2809-2809.	1.4	0
89	Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies. Blood, 2012, 120, 1720-1720.	1.4	1
90	A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure. Blood, 2012, 120, 1719-1719.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents. <i>Blood</i> , 2012, 120, 2035-2035.	1.4	0
92	Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML). <i>Blood</i> , 2012, 120, 309-309.	1.4	0
93	Effector CD4 ⁺ CD45RA ⁺ CD25 ^{bright} Foxp3 ^{bright} Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status.. <i>Blood</i> , 2012, 120, 2808-2808.	1.4	0
94	NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012, 120, 3835-3835.	1.4	0
95	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. <i>Leukemia</i> , 2011, 25, 1147-1152.	7.2	430
96	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. <i>Leukemia Research</i> , 2011, 35, 863-867.	0.8	44
97	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. <i>Journal of Clinical Oncology</i> , 2011, 29, 3322-3327.	1.6	421
98	Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q. <i>Blood</i> , 2011, 118, 2786-2786.	1.4	2
99	Potential of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib. <i>Blood</i> , 2011, 118, 2790-2790.	1.4	2
100	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). <i>Blood</i> , 2011, 118, 609-609.	1.4	8
101	Allogeneic Hematopoietic Peripheral Blood Stem-Cell Transplantation From HLA-Identical Siblings Versus Allelic-Matched Unrelated Donors (10/10 high resolution) in Patients with Acute Myeloid Leukemia and Myelodyplasic Syndrome After Reduced Intensity Conditioning,. <i>Blood</i> , 2011, 118, 4132-4132.	1.4	0
102	Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA). <i>Blood</i> , 2011, 118, 5028-5028.	1.4	0
103	Long-term outcome after bone marrow transplantation for severe aplastic anemia. <i>Blood</i> , 2004, 103, 2490-2497.	1.4	192